T1	intervention 13 42	activated charcoal-epirubicin
T2	total-participants 271 276	Sixty
T3	eligibility 277 321	patients with breast cancer of stages II-III
T4	intervention-participants 359 361	40
T6	control-participants 500 502	20
T5	control 518 536	aqueous epirubicin
T10	outcome 1159 1197	metastatic rate of stained lymph nodes
T11	iv-bin-abs 1248 1251	214
T12	intervention-participants 1252 1255	565
T13	cv-bin-abs 1259 1261	23
T14	control-participants 1262 1264	85
T15	outcome 1007 1066	proportion of the staining lymph nodes with diameter>1.0 cm
T16	iv-bin-abs 1127 1129	96
T17	cv-bin-abs 1137 1140	469
T18	intervention-participants 1130 1133	131
T19	control-participants 1141 1144	519
T20	outcome 941 976	staining rate of the axillary lymph
T21	iv-bin-percent 986 991	86.9%
T22	iv-bin-abs 993 996	565
T23	intervention-participants 997 1000	650
T7	outcome 1296 1350	concentration of epirubicin in the stained lymph nodes
T8	iv-cont-mean 1407 1412	443.0
T26	iv-cont-sd 1415 1420	123.1
T9	cv-cont-mean 1424 1428	31.8
T27	cv-cont-sd 1431 1440	11.9 ng/g
T28	outcome 1462 1474	degeneration
T29	outcome 1479 1487	necrosis
